Abstracts tagged "cathepsin k inhibitor"

Abstract Number: 1026 • 2016 ACR/ARHP Annual Meeting
Morphea-like Skin Lesions Reported in the Phase 3 Long-Term Odanacatib Fracture Trial and Extension in Postmenopausal Women with Osteoporosis
Kenneth G. Saag¹, Tobie de Villiers², Peter Alexandersen³, Heidi Jacobe⁴, Carrie Kovarik⁵, Victoria P. Werth⁶, Albert Leung⁷, Avani Desai-Merchant⁸, Julie Mattaliano⁸ and Deborah Gurner⁸, ¹Department of Medicine, Division of Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL, USA, Birmingham, AL, ²Mediclinic Panorama and Department of Obstetrics & Gynecology, University of Stellenbosch, Cape Town, South Africa, Cape Town, South Africa, ³Center for Clinical and Basic Research, Vejle, Denmark, Ballerup, Denmark, ⁴Department of Dermatology, University of Texas Southwestern Medical Center, Dallas, TX, ⁵Department of Dermatology, University of Pennsylvania, Philadelphia, PA, USA, Philadelphia, PA, ⁶Philadelphia VAMC, Philadelphia, PA, USA, Philadelphia, PA, ⁷Formerly Merck & Co., Inc., Kenilworth, NJ, USA, Kenilworth, NJ, ⁸Merck & Co., Inc., Kenilworth, NJ, USA, Kenilworth, NJ
Background/Purpose: LOFT was a double-blind, placebo-controlled trial. Women ≥65 years with total hip (TH) or femoral neck (FN) bone mineral density (BMD) T-score ≤-2.5, or…
Abstract Number: 1027 • 2016 ACR/ARHP Annual Meeting
Odanacatib Efficacy and Safety in Postmenopausal Women with Osteoporosis: 5-Year Data from the Extension of the Phase 3 Long-Term Odanacatib Fracture Trial
Michael R. McClung¹, Bente Langdahl², Socrates Papapoulos³, Kenneth G. Saag⁴, Henry Bone⁵, Douglas P. Kiel⁶, Kurt Lippuner⁷, Toshitaka Nakamura⁸, Ian Reid⁹, Norman Heyden¹⁰, Carolyn DaSilva¹⁰, Boyd B. Scott¹⁰, Rachid Massaad¹¹, Keith D. Kaufman¹⁰, S. Aubrey Stoch¹⁰, Arthur Santora¹⁰, Deborah Gurner¹⁰ and Antonio Lombardi¹⁰, ¹Oregon Osteoporosis Center, Portland, OR, USA, Portland, OR, ²Aarhus University Hospital, Aarhus, Denmark, Aarhus, Denmark, ³Leiden University Medical Center, Leiden, The Netherlands, Leiden, Netherlands, ⁴University of Alabama at Birmingham, Birmingham, AL, ⁵Michigan Bone & Mineral Clinic, Detroit, MI, USA and The Osteoporosis Center at St. Luke's Hospital, Chesterfield, MO, USA, Detroit, MI, ⁶Institute for Aging Research, Institute for Aging Research, Hebrew Senior Life, Harvard Medical School, Boston, MA, USA, Boston, MA, ⁷Bern University Hospital, Bern, Switzerland, Bern, Switzerland, ⁸University of Occupational and Environmental Health, Fukuoka, Japan, Fukuoaka, Japan, ⁹University of Auckland, Auckland, New Zealand, Auckland, New Zealand, ¹⁰Merck & Co., Inc., Kenilworth, NJ, USA, Kenilworth, NJ, ¹¹MSD Europe Inc., Brussels, Belgium, Brussels, Belgium
Background/Purpose: Long-Term Odanacatib Fracture Trial [Women 65 years of age with BMD T-score ≤–2.5 at total hip (TH) or femoral neck (FN), or with radiographic…
Abstract Number: 343 • 2015 ACR/ARHP Annual Meeting
Efficacy of Odanacatib in Postmenopausal Women with Osteoporosis: Subgroup Analyses of Data from the Phase 3 Long-Term Odanacatib Fracture Trial
Kenneth G. Saag¹, Peter Alexandersen², Claude-Laurent Benhamou³, Nigel Gilchrist⁴, Johan Halse⁵, E. Michael Lewiecki⁶, Kurt Lippuner⁷, Michael McClung⁸, Masataka Shiraki⁹, Carolyn A. DaSilva¹⁰, Nadia Verbruggen¹¹, Boyd B. Scott¹⁰ and Antonio Lombardi¹⁰, ¹University of Alabama at Birmingham, Birmingham, AL, ²Center for Clinical and Basic Research, Vejle, Denmark, Ballerup, Denmark, ³Hôpital d’Orléans-la-Source, Orléans, France, Orleans, France, ⁴The Princess Margaret Hospital, Christchurch, New Zealand, Christchurch, New Zealand, ⁵Osteoporoseklinikken, Oslo, Norway, Oslo, Norway, ⁶New Mexico Clinical Research & Osteoporosis Center, Albuquerque, New Mexico, USA, Albuquerque, NM, ⁷Bern University Hospital, Bern, Switzerland, Bern, Switzerland, ⁸Oregon Osteoporosis Center, Portland, Oregon, USA, Portland, OR, ⁹Research Institute and Practice for Involutional Diseases, Nagano, Japan, Nagano, Japan, ¹⁰Merck & Co., Inc, Kenilworth, NJ, USA, Kenilworth, NJ, ¹¹MSD Europe Inc., Brussels, Belgium, Brussels, Belgium
Background/Purpose: Odanacatib (ODN), a selective oral inhibitor of cathepsin K, is in development for the treatment of osteoporosis. In the Phase 3, Long-Term Odanacatib Fracture…
Abstract Number: 2268 • 2014 ACR/ARHP Annual Meeting
Odanacatib Anti-Fracture Efficacy and Safety in Postmenopausal Women with Osteoporosis: Results from the Phase III Long-Term Odanacatib Fracture Trial
Michael R. McClung¹, Bente Langdahl², Socrates Papapoulos³, Kenneth G. Saag⁴, Silvano Adami⁵, Henry G. Bone⁶, Tobias de Villiers⁷, Douglas P. Kiel⁸, Annie Kung⁹, Prasanna Kumar¹⁰, Sung-Kil Lim¹¹, Xu Ling¹², Kurt Lippuner¹³, Carlos Mautalen¹⁴, Toshitaka Nakamura¹⁵, Jean-Yves Reginster¹⁶, Ian R. Reid¹⁷, José Adolfo Rodríguez-Portales¹⁸, Christian Roux¹⁹, Jesus Walliser²⁰, Nelson B. Watts²¹, José R. Zanchetta²², Cristiano A.F. Zerbini²³, Andrea Rybak-Feiglin²⁴, Dosinda Cohn²⁴, Carolyn A. DaSilva²⁴, Rachid Massaad²⁵, Arthur Santora²⁴, Boyd B. Scott²⁴, Nadia Verbruggen²⁵, Albert Leung²⁶ and Antonio Lombardi²⁴, ¹Oregon Osteoporosis Center, Portland, OR, ²Aarhus University Hospital, Aarhus, Denmark, ³Leiden University Medical Center, Leiden, Netherlands, ⁴Immunology & Rheumatology, The University of Alabama at Birmingham, Birmingham, AL, ⁵Rheumatology Department, University of Verona, Verona, Italy, ⁶Michigan Bone and Mineral Clinic, Detroit, MI, ⁷Stellenbosch University, Stellenbosch, South Africa, ⁸Institute for Aging Research, Hebrew Senior Life, Harvard Medical School, Boston, MA, ⁹University of Hong Kong, Pokfulam, Hong Kong, China, ¹⁰Bangalore Diabetes Centre, Bangalore, India, ¹¹Yonsei University, Seoul, South Korea, ¹²Peking Union Medical College Hospital, Beijing, China, ¹³Bern University Hospital, Bern, Switzerland, ¹⁴Centro de Osteopatías Médicas, Buenos Aires, Argentina, ¹⁵University of Occupational & Environmental Health, Fukuoaka, Japan, ¹⁶CHU-Centre Ville, Policliniques BRULL, Liege, Belgium, ¹⁷Department of Medicine, University of Auckland, Auckland, New Zealand, ¹⁸Pontificia Universidad Católica de Chile, Santiago, Chile, ¹⁹Paris Descartes University, Cochin Hospital, Paris, France, ²⁰Bone Metabolism Clinic, Hospital Angeles del Pedregal, Mexico City, Mexico, ²¹Mercy Health Osteoporosis and Bone Health Services, Cincinnati, OH, ²²IDIM Instituto de Investigaciones Metabolicas, Buenos Aires, Argentina, ²³Centro Paulista de Investigações Clinicas, São Paulo, Brazil, ²⁴Merck Sharp and Dohme Corp., Rahway, NJ, ²⁵MSD Europe Inc., Brussels, Belgium, ²⁶Clinical Research, Merck Sharp and Dohme Corp., Rahway, NJ
Background/Purpose: Odanacatib (ODN), a selective oral inhibitor of cathepsin K, is in development for the treatment of osteoporosis. The Phase III Long-Term Odanacatib Fracture Trial…
Abstract Number: 1219 • 2013 ACR/ARHP Annual Meeting
Phase 3 Fracture Trial Of Odanacatib For Osteoporosis – Baseline Characteristics and Study Design
Socrates Papapoulos¹, Henry G. Bone², David W. Dempster³, John Eisman⁴, Susan Greenspan⁵, Michael McClung⁶, Toshitaka Nakamura⁷, Joseph Shih⁸, Albert Leung⁹, Arthur Santora¹⁰, N. Verbruggen¹¹ and Antonio Lombardi¹², ¹Leiden University Medical Center, Leiden, Netherlands, ²Michigan Bone and Mineral Clinic, Detroit, MI, ³Regional Bone Center, Helen Hayes Hospital, West Haverstraw, NY, ⁴The Garvan Institute of Medical Research, Sydney, Australia, ⁵University of Pittsburgh, Pittsburgh, PA, ⁶Oregon Osteoporosis Center, Portland, OR, ⁷University of Occupational & Environmental Health, Fukuoaka, Japan, ⁸Robert Wood Johnson Medical School, Piscataway, NJ, ⁹Clinical Research, Merck Sharp and Dohme Corp., Rahway, NJ, ¹⁰Merck Sharp & Dohme Corp., Whitehouse Station, NJ, ¹¹MSD Belgium, Brussels, Belgium, ¹²Merck Sharp and Dohme Corp., Rahway, NJ
Background/Purpose: Odanacatib is a selective and reversible inhibitor of cathepsin K; a collagenase secreted by osteoclasts, and is currently being evaluated for the treatment of…
Abstract Number: 1224 • 2013 ACR/ARHP Annual Meeting
Prednisone Has No Effect On Odanacatib Pharmacokinetics In Healthy Subjects
Gene Marcantonio¹, Chengcheng Liu², Stefan Zajic³, Chantal Mahon², David Hreniuk², Anish Mehta⁴, Kate Mostoller², Denise Morris⁵, Hongwei Xue⁵ and S. Aubrey Stoch², ¹Merck & Co., Whitehouse Station, NJ, ²Merck Sharp & Dohme Corp., Whitehouse Station, NJ, ³Merck Sharp & Dohme Corp, Whitehouse Station, NJ, ⁴Merck Sharp & Dohme Corp.,, Whitehouse Station, NJ, ⁵Covance, Madison, WI
Background/Purpose: We evaluated the effect of prednisone, a glucocorticoid believed to induce the CYP P450 enzyme, on the pharmacokinetics of odanacatib, a novel Cathepsin K…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].